Meetings with Marjorie Michel reported by registered lobbyists. Lobbyists must report every oral, arranged meeting with an MP, minister or other designated public office holder.
← Marjorie MichelEvery reported meeting
Newest first, back to November 2021 if Marjorie Michel held office then.
-
Reported by Bettina Hamelin · In-house (organization)
- Karim Bardeesy · Member of Parliament
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs and One Canadian Economy, Privy Council Office (PCO)
- Marjorie Michel · Minister of Health, Health Canada (HC)
- Janice Charette · Chief Trade Negotiator to the United States, Privy Council Office (PCO)
and 7 moreShow fewer
- Ritu Banerjee · Assistant Deputy Minister, Health Emergency Readiness Canada, Innovation, Science and Economic Development Canada (ISED)
- Martin Moen · Assistant Associate Deputy Minister, Trade Policy and Negotiations, Global Affairs Canada (GAC)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
- Sandenga Yeba · Deputy Chief of Staff and Director of Policy to the Minister of Health, Health Canada (HC)
- Justine Frame · Policy Advisor, Office of the Minister of Health, Health Canada (HC)
- Shalene Curtis-Micallef · Deputy Minister, Health, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
Free trade agreements as they relate to the biopharmaceutical industry
-
Reported by David D. Jones · In-house (corporation)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
- Karim Bardeesy · Member of Parliament
- Marjorie Michel · Minister of Health, Health Canada (HC)
- Janice Charette · Chief Trade Negotiator to the United States, Privy Council Office (PCO)
and 7 moreShow fewer
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Martin Moen · Associate Asst Dep. Minister, Trade Policy and Negotiations, Global Affairs Canada (GAC)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Justine Frame · Special Assistant- Policy, Health Canada (HC)
- Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework. Read more
Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting.
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH).
US - Canada Regulatory Cooperation Council (RCC) as it relates to the regulation of biopharmaceutical products.
Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive.
Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products.
Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products.
Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry, and related updates and to Federal budgetary policy.
Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals.
-
Reported by Brigitte Nolet · In-house (corporation)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
- Marjorie Michel · Minister of Health
- Karim Bardeesy · Member of Parliament
- Janice Charette · Chief Trade Negotiator to the United States, House of Commons
and 7 moreShow fewer
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Martin Moen · Assistant Associate Deputy Minister, Trade Policy and Negotiations, Global Affairs Canada, Global Affairs Canada (GAC)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Justine Frame · Special Assistant, Policy, Health Canada (HC)
- Shalene Curtis-Micallef · Deputy Minister, Health, Health Canada (HC)
Monitoring and engaging the Government and Parliamentarians on policies and programs that would provide greater clarity and predictability in the tax outcomes and improvements to tax measures such as the Manufacturing & Processing (M&P) credit and the Scientific Research & Developmental (SR&ED). Read more
-
Reported by Paul Petrelli · In-house (corporation)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
- Karim Bardeesy · Member of Parliament
- Marjorie Michel · Minister of Health, Health Canada (HC)
- Janice Charette · Chief Trade Negotiator to the United States, Privy Council Office (PCO)
and 7 moreShow fewer
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Martin Moen · Associate Assistant Deputy Minister, Intergovernmental Affairs Secretariat (IGA)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Justine Frame · Special Assistant, Policy, Health Canada (HC)
- Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector Read more
Free Trade agreements as they relate to the biopharmaceutical industry
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.
-
Reported by Arima Ventin · In-house (corporation)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
- Karim Bardeesy · Member of Parliament
- Marjorie Michel · Minister of Health, Health Canada (HC)
- Janice Charette · Chief Trade Negotiator to the United States, Global Affairs Canada (GAC)
and 7 moreShow fewer
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Martin Moen · Assistant Associate Deputy Minister, Trade Policy and Negotiations, Global Affairs Canada (GAC)
- Manuela Tomic · Senior Policy Advisor, Office of the Minister of Industry, Innovation, Science and Economic Development Canada (ISED)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Justine Frame · Policy Advisor, Health Canada (HC)
- Shalene Curtis-Micallef · Deputy Minister of Health, Health Canada (HC)
Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape. Read more
Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.
Communication regarding free trade agreements as they relate to the biopharmaceutical industry.
Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.
Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.
The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.
Innovation, Science and Economic Development (ISED)'s Health Emergency Readiness program, insofar as it pertains to growth and development of the life sciences industry in Canada.
Communications regarding intellectual property protection of prescription drugs, including the Patent Act, the Patented Medicines Regulations, the Patented Medicine Notice of Compliance (PMNOC) Regulations, the Patent Term Adjustment regime and Health Canada’s Data Protection regime.
-
Reported by Gaby Bourbara · In-house (corporation)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs, Global Affairs Canada (GAC)
- Marjorie Michel · Minister of Health, Health Canada (HC)
- Karim Bardeesy · Member of Parliament
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
and 9 moreShow fewer
- Martin Moen · Associate Assistant Deputy Minister, Global Affairs Canada (GAC)
- Loris Mirella · Director, Intellectual Property, Trade Policy, Global Affairs Canada (GAC)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Janice Charette · Chief Trade Negotiator to the US, Global Affairs Canada (GAC)
- Shalene Curtis Micallef · Deputy Minister, Health Canada (HC)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Justine Frame · Special Assistant, Policy, Health Canada (HC)
- Daniel MacDonald · Director General, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
-
Reported by James Keon · In-house (organization)
- Marjorie Michel · Minister of Health, Health Canada (HC)
Health Canada with respect to its Regulatory Systems Review for Therapeutic Products. Read more
Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals.
-
Reported by Terry Creighton · Consultant
- Marjorie Michel · Minister of Health, Health Canada (HC)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
- Shalene Curtis-Micallef · Deputy Minister of Health, Health Canada (HC)
Advocate for supportive economic and tax policy for Canada's pharmaceutical manufacturing sector. Read more
Advocate for regulatory policy to support review of generic drug submissions from Canadian drug producers
Work with government to promote and support Canada’s pharmaceutical manufacturing sector and advocating for supportive public policy
Raise awareness of role of Canadian drug producers in exports to the U.S. and other parts of the world. Advocate for including Canada's drug exports as part of CUSMA negotiations
-
Reported by David Goodman · In-house (corporation)
- Marjorie Michel · Ministre de la Santé, Health Canada (HC)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by Alex Munter · In-house (organization)
- Marjorie Michel · Minister of Health
TECHNOLOGY AND ARTIFICIAL INTELLIGENCE: provide CMA’s perspective on the impact of technology and artificial intelligence on the health care sector and the means through which advancements can be foreseen and managed. Read more
-
Reported by Margot Burnell · Consultant
- Marjorie Michel · Federal Minister of Health
DIGITAL HEALTH: Increased investment in providing digital, virtual and telehealth services.
-
Reported by Alex Munter · In-house (organization)
- Marjorie Michel · Minister of Health, Health Canada (HC)
DIGITAL HEALTH: Increased investment in providing digital, virtual and telehealth services.
-
Reported by Lindsay Brumwell · In-house (organization)
- Andréanne Larouche · Member of Parliament
- Giovanna Mingarelli · Member of Parliament
- Maggie Chi · Parliamentary Secretary, Health Canada (HC)
- Marjorie Michel · minister of health, Health Canada (HC)
and 7 moreShow fewer
- Paulette Senior · Senator, Senate of Canada
- Lisa Xie · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Aishma Suleman · Legislative Assistant, House of Commons
- Shanzae Khan · Deputy Director of Operations, Health Canada (HC)
- Elina Li · Parliamentary Secretary Assistant, Health Canada (HC)
- Nora Draper · Parliamentary Secretary Assistant, Health Canada (HC)
- Guillaume Bertrand · Director of Communications, Health Canada (HC)
Research and share information from Equal Voice's election tracker and other research projects and initiatives (e.g. national polling). Read more
Addressing the barriers faced by women and gender diverse people seeking, and serving in elected office, such as financial, harassment, gender bias.
-
Reported by Pierre Petelle · In-house (organization)
- Marjorie Michel · Minister of Health
- Buckley Belanger · Secretary of State (Rural Development), Innovation, Science and Economic Development Canada (ISED)
- Nancy Hamzawi · President, Health Canada (HC)
Forward policy and implementation. We are seeking policies and programs that are supportive of plant science technologies.
-
Reported by Ken Seitz · In-house (corporation)
- Buckley Belanger · Secretary of State (Rural Development), Innovation, Science and Economic Development Canada (ISED)
- Marjorie Michel · Minister of Health, Health Canada (HC)
- Nancy Hamzawi · President, Public Health Agency of Canada (PHAC)
- Jaeda Schilke · Regional Advisor, Health Canada (HC)
Input regarding policies that enhance or impede the competitiveness of Canada's agriculture and fertilizer industries.
-
Reported by Vince Bruni-Bossio · In-house (organization)
- Buckley Belanger · Secretary of State (Rural Development), Innovation, Science and Economic Development Canada (ISED)
- Marjorie Michel · Minister, Health Canada (HC)
Continue and increase funding to the Indirect Costs of Research Program in order to maintain an internationally competitive research and development infrastructure Read more
Discuss post-secondary institutions' role in securing Canada's water future through education and research.
Funding for research and campus infrastructure
-
Reported by Dr. Larry Rosia · In-house (organization)
- Buckley Belanger · Secretary of State (Rural Development), Innovation, Science and Economic Development Canada (ISED)
- Marjorie Michel · Minister of Health, Health Canada (HC)
- Nancy Hamzawi · President, Public Health Agency of Canada (PHAC)
- Jaeda Schilke · Regional Advisor for West & North, Health Canada (HC)
Seeking funding for educational programs offered through Saskatchewan PolyTechnic
-
Reported by Vince Bruni-Bossio · In-house (organization)
- Buckley Belanger · Secretary of State (Rural Development), Innovation, Science and Economic Development Canada (ISED)
- Marjorie Michel · Minister, Health Canada (HC)
- Nancy Hamzawi · Executive Vice-President, Public Health Agency of Canada (PHAC)
Continue and increase funding to the Tri-Agency (CIHR, NSERC, SSHRC) in order to maintain an internationally competitive research and development infrastructure. Read more
Seek funding and support for the institution’s teaching, and research and development enterprise in life sciences, basic and applied sciences, social sciences, humanities and fine arts and mental health.
-
Reported by Viviane Poupon · In-house (organization)
- Marjorie Michel · Minister of Health, Health Canada (HC)
Brain Canada Foundation is seeking a top-up to its current funding to support the development and application of AI to accelerate research, advance our understanding of the brain, and identify solutions for brain diseases and disorders. Read more
Brain Canada Foundation is seeking additional funding to increase the Canada Brain Research Fund, which is currently funded by the Government of Canada, through Health Canada, and which current funding expires March 31, 2028.
-
Reported by Pierre Petelle · In-house (organization)
- Marjorie Michel · Minister of Health
Forward policy and implementation. We are seeking policies and programs that are supportive of plant science technologies.
-
Reported by An Van Gerven · In-house (corporation)
- Jean-Yves Duclos · Member of Parliament
- Steeve Lavoie · Député
- Marjorie Michel · Ministre de la Sante, Health Canada (HC)
Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy Read more
Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policy
-
Reported by Andrea Seale · In-house (organization)
- Marjorie Michel · Minister of Health, Health Canada (HC)
- Greg Orencsak · Deputy Minister, Health Canada (HC)
Data as it relates to all health and cancer data policy, planning and outcomes.
-
Reported by Sylvia Durgerian · In-house (corporation)
- Marjorie Michel · Minister of Health
Related to the life sciences, research and the digital ecosystems, we need to make sure that Canada creates an environment that is globally competitive
-
Reported by Rami Fayed · In-house (corporation)
- Jean-Yves Duclos · Member of Parliament
- Steeve Lavoie · Member of Parliament
- Marjorie Michel · Minister of Health, Health Canada (HC)
- Guillaume Bertrand · Director of Communications, Health Canada (HC)
Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape. Read more
Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.
Communication regarding free trade agreements as they relate to the biopharmaceutical industry.
-
Reported by Albert Falardeau · In-house (organization)
- Marjorie Michel · Ministre de la Santé, Health Canada (HC)
Démarches afin de positionner les grossistes en pharmacie du Québec comme des partenaires potentiels de choix pour soutenir les objectifs du gouvernement d’améliorer l’efficience de la chaîne logistique du médicament, notamment par des solutions d’entreposage d’ingrédients pharmaceutiques actifs, de médicaments, de dispositifs médicaux ou d’autres fournitures en cas de crises ou de pandémies futures. Read more
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.